GeNeuro touts a mixed set of extension data in a shot at salvaging their failed mid-stage MS drug
Geneva-based GeNeuro managed to earn a spike in its share price after touting a distinctly mixed set of Phase IIb extension data for their failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
